Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure

Journal of the American College of Cardiology

Volumn 42, Issue 1, 2003, Pages 133-139

  Castellani, Sergio ^a,c   Paniccia, Rita ^a   Di Serio, Claudia ^b   La Cava, Giuseppe ^b   Poggesi, Loredana ^a   Fumagalli, Stefano ^b   Gensini, Gian Franco ^a   Neri Serneri, Gian Gastone ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c Clin Medica Generale e Cardiologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANRENOATE POTASSIUM; CREATININE; DIGOXIN; FUROSEMIDE; PICOTAMIDE; PLACEBO; PROSTAGLANDIN H2; THROMBOXANE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE B2; THROMBOXANE SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; LUNG PRESSURE; MALE; METABOLITE; NATRIURESIS; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY EXCRETION; VENOUS PRESSURE;

EID: 0038205721     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00511-4     Document Type: Article

References (32)

1. Holmer SR, Riegger AJ, Notheis WT, Kromer EP, Kochsiek K. Hemodynamic changes and renal plasma flow in early heart failure: implications for renin, aldosterone, norepinephrine, atrial natriuretic peptide and prostacyclin. Basic Res Cardiol 1987;82:101-8.
2. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy. N Engl J Med 1988;319:1065-72.
3. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992;85:510-7.
4. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circ Res 1981;63:645-51.
5. Merrill AJ. Mechanisms of salt and water retention in heart failure. Am J Med 1994;6:357-61.
6. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 1984;55:669-75.
7. Cody RJ, Ljungman S, Covit AB, et al. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int 1988;34:361-7.
8. Riegger AJ. Role of prostaglandins in regulation of kidney function in heart failure. Herz 1991;16:116-23.
9. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 984;310:347-52.
10. 2α in heart failure. Am Heart J 1997;133:94-100.
11. 2 and prostaglandin endoperoxide analogue effects on porcine renal blood flow. Am J Physiol 1990;258:F109-14.
12. 2 and NO. Am J Physiol 2000;279:F302-8.
13. Hably C, Menz V, Bartha J. Cardiac output distribution and intrarenal hemodynamics: role of thromboxanes. Acta Physiol Hung 1991;78: 89-98.
14. Welch WJ, Wilcox CS. Potentiation of tubuloglomerular feed-back in the rat by thromboxane mimetic. J Clin Invest 1992;89:1857-65.
15. Zipser RD. Effects of selective inhibition of thromboxane synthesis on renal function in humans. Am J Physiol 1985;248:F753-6.
16. 2 receptor antagonist. Br J Pharmacol 1994;112:81-6.
17. Balsano F, Violi F, the ADEP Group. Effect of picotamide on the clinical progression of peripheral vascular disease: a double-blind placebo-controlled study. Circulation 1993;87:563-9.
18. Giustina A, Perini P, Desenzani P, et al. Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 1998;47:423-30.
19. Cocozza M, Picano T, Oliviero U, Russo N, Coto V, Milani M. Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution: a two-year, double-blind, placebo-controlled study in diabetic patients. Stroke 1995;26:597-601.
20. 2 after angiotensin converting enzyme inhibition in hypertensive patients. Prostaglandins Leukot Med 1986;21:77-86.
21. Ihara E, Hirajno K, Derkah DN, et al. The mechanism of bradykinin-induced endothelium dependent contraction and relaxation in the porcine interlobar renal artery. Br J Pharmacol 2000;129:943-52.
22. Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998;98:2290-5.
23. Kitabatake A, Inoue M, Asao M, et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983;68:302-9.
24. Currie PJ, Seward JB, Chang KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985;6:750-6.
25. Hussey HH, Jegers H. Practical considerations of venous pressure. N Engl J Med 1947;237:776-80.
26. Sapirstein LA, Vidt DG, Mandel MJ, et al. Volumes of distribution and clearances of intravenously injected creatine in a dog. Am J Physiol 1955;181:330-6.
27. Castellani S, Del Rosso A, Chen JL, et al. The renal excretory activity of atrial natriuretic factor is independent of renal prostaglandins in humans. Prostaglandins Leukot Essent Fatty Acids 1991;42:23-9.
28. Castellani S, Ungar A, La Cava G, et al. Renal adaptation to stress: a possible role of endothelin release and prostaglandin modulation in the human subject. J Lab Clin Med 1997;129:462-9.
29. GLM Repeated Measures. In: SPSS Advanced Models 9.0. Chicago, IL: SPSS Inc., 1999:15-32.
30. Fitzgerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and rhromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67:1174-7.
31. Badahaman AH, Wilson TW. A renal vasodilator effect of angiotensin II revealed by dual thromboxane inhibition. Can J Physiol Pharmacol 1994;72:632-6.
32. Zoja C, Perico N, Coma D, et al. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. J Am Soc Nephrol 1990;1:799-807.